Meta-analysis of Fuzheng jiedu therapy of traditional Chinese medicine in the treatment of advanced non-small cell lung cancer
- VernacularTitle:中医扶正解毒法治疗晚期非小细胞肺癌的Meta分析
- Author:
Zhuo LI
1
;
Ling QIAO
1
;
Yijie WANG
1
;
Wei WANG
1
Author Information
1. TCM Cancer Treatment Center，Chongqing University Cancer Hospital，Chongqing 400030，China
- Publication Type:Journal Article
- Keywords:
Fuzheng jiedu therapy;
advanced non-small
- From:
China Pharmacy
2024;35(13):1651-1657
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the therapeutic effects of Fuzheng jiedu therapy of traditional Chinese medicine （TCM） in the treatment of advanced non-small cell lung cancer （NSCLC）. METHODS Randomized controlled trials on the treatment of NSCLC with Fuzheng jiedu therapy of TCM+conventional chemotherapy （trial group） versus conventional chemotherapy （control group） were collected by searching PubMed， CBM， China Periodicals Full Text Database， VIP and Wanfang data service platform during the inception-Oct.Two researchers respectively screened the literature and extracted data， evaluated the quality according to Cochrane 5.4 tool， and used RevMan 5.3 software to perform meta-analysis on the data. RESULTS Nineteen pieces of literature were finally included in the study； meta-analysis showed disease control rate [RR＝1.15， 95%CI （1.07， 1.23）， P＝ 0.000 1]， objective remission rate [RR＝1.47， 95%CI （1.29， 1.67）， P＜0.000 01]， Karnofsky performance scores [WMD＝6.11， 95%CI （2.97， 9.25）， P＝0.000 1]， the levels of immune function indexes （CD3+， CD4+， CD4+/CD8+）， inflammatory factor indicators [interleukin-2 （IL-2）， interferon-γ （IFN-γ）] and lung function indexes （forced vital capacity， forced expiratory volume in the first second and peak expiratory flow） in the trial group were higher than control group （P＜0.05）. The symptomatic score [WMD＝－2.83， 95%CI （－4.42， －1.24）， P＝0.000 5]， the levels of IL-6 [WMD＝－11.20， 95%CI （－21.75，－0.64）， P＝ 0.04]， and the incidence of ADRs （myelosuppression， hepatic and renal injury， gastrointestinal reactions in trial group were all lower than control group （P＜0.05）. In addition， the levels of natural killer cells in the trial group were higher than the control group， but the results were not statistically significant （P＞0.05）. CONCLUSIONS Compared with conventional chemotherapy， Fuzheng jiedu therapy of TCM combined with conventional chemotherapy has obvious advantages in increasing the disease control rate and objective remission rate， improving the quality of life， promoting TCM syndrome and inflammatory status，enhancing immunity and lung function， and decreasing the incidence of ADRs in NSCLC patients.
